KDR and glioma: Although BEV treatments performed in mouse models are limited in that only human VEGF-A secreted by the xenografted glioma cells is blocked, we found dramatically reduced antiangiogenic effects of BEV in VEGFR-2-positive gliomas, while the absence of VEGFR-2 led to a highly instable vascular system susceptible to abrogation with BEV.